Experimental cancer drug ART0380 trial halted early
NCT ID NCT05798611
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The drug was taken by mouth and aimed to shrink tumors by blocking a protein involved in cancer cell growth. The trial was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ART0380 (an ATR kinase inhibitor taken orally)
What this could lead to
If successful, ART0380 could offer a new treatment option for people with advanced solid tumors that have specific genetic features.
What could go wrong
This trial was terminated early, so results are limited. The drug is still experimental, and its safety and effectiveness are not yet proven. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Francois Baclesse - Service d'Oncologie médicale
Caen, NAP, 14076, France
-
Centre Hospitalier Universitaire De Poitiers
Poitiers, NAP, 86000, France
-
Dana Farber Cancer Center
Boston, Massachusetts, 02215, United States
-
Fundación Instituto Valenciano De Oncología
Valencia, 46009, Spain
-
Hopital Cochin Saint Vincent De Paul
Paris, NAP, 75014, France
-
Hopital Lyon Sud
Pierre-Bénite, NAP, 69310, France
-
Hospital Universitario De Jaén
Jaén, Andalusia, 23007, Spain
-
Institut de Cancérologie de l'Ouest
Angers, NAP, 49055, France
-
Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital - Oncology
New York, New York, 10065, United States
-
Northwell Health R.J. Zuckerberg Cancer Center
Lake Success, New York, 11042, United States
-
The University of Chicago
Chicago, Illinois, 60637-1447, United States
-
University of California Los Angeles (UCLA)
Los Angeles, California, 90095-1781, United States
-
University of Oklahoma/Sarah Cannon Research Institute
Oklahoma City, Oklahoma, 73104, United States
-
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224, United States
-
Women and Infants Hospital
Providence, Rhode Island, 02905, United States